Mannkind Corp (MNKD) 5.47 $MNKD After Hours Gainers /

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mannkind Corp (MNKD) 5.47 $MNKD

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST

VEEV: 24.63 (-0.10), NG: 3.26 (-0.19), CRIS: 3.04 (-0.29), EVTC: 21.77 (+0.27), GTN: 12.60 (+0.29), SM: 44.49 (-1.81), MNKD: 5.47 (-0.26), RIGL: 3.56 (+0.26), EXK: 1.96 (-0.09), WBAI: 14.50 (+0.70)

Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), ARWR: 7.75 (-0.19), SPHS: 0.70 (-0.03), BSX: 16.56 (-0.41), MDVN: 126.55 (-0.53), JNJ: 100.11 (-2.41), AAC: 29.30 (-2.80), ABBV: 55.64 (-1.22), SNY: 47.42 (-0.94), SMMT: 10.29 (+0.10), ARNA: 4.32 (+0.09), XLRN: 40.55 (-0.79), MNK: 121.33 (-0.37), AQXP: 10.49 (+0.43), PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), GSK: 46.73 (-0.87), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), CELG: 118.03 (-2.68), OREX: 7.10 (-0.91), PODD: 32.24 (+0.26), GERN: 3.50 (-0.28), TEVA: 56.40 (-0.11), TCON: 17.57 (+0.36), NVS: 97.46 (-1.49)

Technical Analysis of Wal-Mart, Coca-Cola, MannKind and Las Vegas Sands
Kumar Abhishek - Amigobulls - Thu Mar 05, 7:02AM CST
Coca-Cola stock price has again found support at 100 day SMA. The 100 day SMA has provided support to coca cola stock price on multiple occasions.
KO: 41.52 (-0.88), WMT: 82.59 (-0.98), LVS: 55.09 (-1.27), MNKD: 5.47 (-0.26)

5 Things MannKind Corporation's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 05, 6:21AM CST
MannKind 's fourth-quarter conference was only 31 minutes long, but the call contained some tidbits of insight from the biotech's management that investors should know. Source: MannKind. "In fact, we were just, the other day, asked if we...
SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)

MannKind: Use This Drop As An Opportunity
Kumquat Research - at Seeking Alpha - Wed Mar 04, 7:33AM CST

MNKD: 5.47 (-0.26)

MannKind's Charts Suggest Waiting on the Stock After Goldman's Downgrade
at The Street - Tue Mar 03, 3:22PM CST
Here's a technical look at the stock after a brutal downgrade.
MNKD: 5.47 (-0.26)

New Buy Ins And Profit Taking: The Well-Valued Growth Portfolio This Month
Psycho Analyst - at Seeking Alpha - Tue Mar 03, 1:05PM CST

ODFL: 77.51 (-0.13), ESRX: 82.27 (-2.01), THO: 61.35 (-0.02), SWKS: 90.75 (-0.80), LGIH: 13.66 (-0.23), LKQ: 23.83 (-0.32), DG: 71.32 (-0.39), MNKD: 5.47 (-0.26), LUV: 43.30 (-0.80)

Why MannKind Corp. Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Tue Mar 03, 10:48AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of  MannKind Corp.    fell by more than 14% on...
GS: 186.91 (-3.17), SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)

Potential Afrezza discounts and challenging competitive landscape behind Goldman downgrade of MannKind
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 10:46AM CST

LLY: 68.41 (-2.18), SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)

Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'
at The Street - Tue Mar 03, 10:28AM CST
Cramer says the negative Goldman Sachs is having an unhealthy effect on MannKind's stock.
MNKD: 5.47 (-0.26)

Forget Biased Analysts, Diabetics Love MannKind's Afrezza
Maredin Capital Advisors - Seeking Alpha - Tue Mar 03, 9:32AM CST
The MannKind (ticker " MNKD " story/plot continues to thicken Over the past several years, investors, both long and short, have had to rely on trial data, and the opinions of analysts to guide their investment decisions. This led to a...
MNKD: 5.47 (-0.26)

MannKind off 10% premarket on Goldman downgrade
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:24AM CST

MNKD: 5.47 (-0.26)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST

MDR: 3.32 (-0.05), ONCY: 0.90 (-0.15), PLUG: 2.97 (+0.01), OCN: 8.91 (+0.24), XON: 50.16 (+0.66), TEDU: 10.24 (+0.21), BIOC: 3.10 (-0.26), LL: 33.32 (-0.51), MNKD: 5.47 (-0.26), CYCC: 1.05 (-0.01), CYTX: 1.11 (-0.05), DATE: 5.06 (-0.04), TSEM: 17.50 (-0.31), LEAF: 48.59 (-1.19), FNJN: 2.42 (-0.10), AMCO: 1.28 (-0.02)

MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch
at The Street - Tue Mar 03, 7:16AM CST
The slow commercial launch of the inhaled insulin Afrezza coupled with growing downward pricing pressure for all diabetes products compels Goldman Sachs to slap a 'sell' rating on MannKind.
SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)

Downgrade Alert for MannKind (MNKD)
Comtex SmarTrend(R) - Tue Mar 03, 7:00AM CST
MannKind (NASDAQ:MNKD) was downgraded from Neutral to Sell at Goldman Sachs today. The stock closed yesterday at $6.64 on volume of 6.1 million shares, below average daily volume of 6.3 million. MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Companys lead investigational product candidate is the Technosphere Insulin System.
MNKD: 5.47 (-0.26)

Institutions Lend Out MannKind Shares To Make Profits But Depress The Price As Well
Austin Moss - at Seeking Alpha - Mon Mar 02, 9:57AM CST

MNKD: 5.47 (-0.26)

MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
at The Street - Mon Mar 02, 7:15AM CST
Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.
NVO: 46.51 (-0.33), LLY: 68.41 (-2.18), SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)

Analysts Weigh In On MannKind Following Q4 Results
TipRanks - at Seeking Alpha - Sat Feb 28, 7:32AM CST
By Carly Forster MannKind Corporation (NASDAQ: MNKD ) announced its fourth-quarter fiscal 2014 earnings report on Wednesday, February 24th, with results generally in line with expectations. Highlights from the report include a loss of -$0.09 a...
MNKD: 5.47 (-0.26)

Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.80 (-0.11), VRX: 198.71 (-5.24), ACT: 289.92 (-5.78), PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), CAH: 87.01 (-1.94), CLDX: 29.39 (-0.39), HSP: 87.90 (+0.05), AGN: 233.51 (-1.90), JNJ: 100.11 (-2.41), ATOS: 1.97 (-0.04), ONVO: 5.59 (-0.13), PTCT: 71.13 (-1.59), SNY: 47.42 (-0.94), PTLA: 41.72 (-0.13), INCY: 90.00 (-1.97), PFE: 33.97 (-0.50), CPHR: 11.67 (-0.33), MYL: 55.44 (-1.25), AMGN: 154.88 (-4.72), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), NKTR: 13.02 (-0.28), OMER: 26.14 (-0.21), DVA: 77.63 (+0.70), GILD: 101.81 (-1.61), SGEN: 35.32 (-0.28), ACHN: 11.39 (+0.40), MRK: 56.84 (-1.14), TEVA: 56.40 (-0.11), BIL: 45.72 (-0.01), ARIA: 8.08 (-0.17), NVS: 97.46 (-1.49)

Why Second Sight Medical Products Inc. Vaulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 27, 12:41PM CST
Although we don't believe in   timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Al Mann's vision-restoring...
EYES: 17.44 (+0.37), MNKD: 5.47 (-0.26)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 31

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 61

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 48

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 35

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 44

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 51

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 71

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 139

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytek Biosciences Prepares for Q2 2025 Financial Results Report

Updated Category News Views 214

Cytek Biosciences Plans Financial Disclosure for Second Quarter 2025 Cytek Biosciences, Inc. (NASDAQ: CTKB), based in Fremont, California, has dynamic news for stakeholders. The company is set to disclose its financial results for the second quarter of 2025 on August 6, 2025. This critical deadline follows the market closure that day, allowing for a comprehensive analysis...

Continue Reading
Alliance Trust PLC Shares Up: Latest NAV Per Share Insights

Updated Category News Views 171

Alliance Trust PLC Alliance Trust PLC's recent trading data dropped some key numbers that had traders buzzing. The Net Asset Value (NAV) per ordinary share hit the screens, giving everyone a fresh angle on how the company was really performing in a choppy market. NAV Breakdown: What's It Telling Us? Here's how the NAV shook out on the latest report: Valued on a Bid Price...

Continue Reading
Man Group Investment Insights: Spirent Communications and Trends

Updated Category News Views 199

Investment Insights from Man Group regarding Spirent Communications In today’s evolving market, understanding the dynamics between significant firms like Man Group PLC and Spirent Communications plc is vital for investors. This disclosure provides a snapshot of Man Group’s holdings and interests, particularly in relation to investing more than 1% in relevant...

Continue Reading
Sunny Lowe Joins Prime Mining Corp's Board of Directors

Updated Category News Views 221

Prime Mining Corp. (TSX: PRYM) (Other OTC: PRMNF) (Frankfurt: O4V3) has recently appointed Sunny Lowe to its Board of Directors. This announcement highlights a strategic move by the company to strengthen its leadership team as it continues its key projects, particularly the Los Reyes Project. Welcome to Sunny Lowe Murray John, Chair of the Board, expressed enthusiasm...

Continue Reading
Spotlight on Magnificent 7 Stocks: Opportunities in a Turbulent Market

Updated Category News Views 190

Market Overview: Understanding the Current Landscape The technology sector has seen major fluctuations recently, prompting discussions about the best investment opportunities. Economic uncertainties and market instability have resulted in significant stock losses, making this a pivotal moment for investors. The backdrop of Trump’s trade policies adds another layer of...

Continue Reading